Hanna Eriksson

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Docent i Onkologi. Överläkare i onkologi, Tema Cancer, Karolinska
Universitetssjukhuset.

Forskningsbeskrivning

Vår grupp inriktar sig på klinisk och translationell melanomforskning.
Länk till forskargruppen Hanna Eriksson's Group | Karolinska Institutet
(ki.se) [1]

Undervisning

Huvudhandledare för doktorander och postdocs.
Organiserar doktorandkurserna:
Clinical Oncology for Pre-Clinical Doctoral Students (#5505), Karolinska
Institutet.
Basic Course in Tumor Biology and Oncology (#3112), Karolinska Institutet.

Artiklar

Article: JOURNAL OF AMERICAN ACADEMY OF DERMATOLOGY. 2024;90(5):963-969
Loss in life expectancy in patients with stage II-III cutaneous melanoma in Sweden: A population-based cohort study
Vikstrom S; Syriopoulou E; Andersson TM-L; Eriksson H
Journal article: ACTA ONCOLOGICA. 2024;63:24179-219
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study
Miceli R; Eriksson H; Lo Russo G; Alfieri S; Bjaanaes MM; Pietrantonio F; De Cecco L; Prelaj A; Proto C; Franzen J; McDonnell D; Pina JJB; Beninato T; Mazzeo L; Giannatempo P; Verzoni E; Crown J; Helland A; Eustace AJ
Article: EUROPEAN JOURNAL OF CANCER. 2024;200:113601
Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy
Egeler M; Lai-Kwon J; Tissier R; Fraterman I; Kuijpers A; Van Houdt W; Wilgenhof S; Rao A; Sandhu S; Lee R; Eriksson H; van Leeuwen M; de Ligt K; van Akkooi A; van de Poll-Franse L
Article: BRITISH JOURNAL OF DERMATOLOGY. 2023;189(6):702-709
Increasing melanoma incidence and survival trend shifts with improved melanoma-specific survival between 1990 and 2020 in Sweden
Vikstrom S; Mikiver R; Lapins J; Nielsen K; Vassilaki I; Lyth J; Isaksson K; Eriksson H
Article: ANNALS OF ONCOLOGY. 2023;34(4):420-430
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
Versluis JM; Menzies AM; Sikorska K; Rozeman EA; Saw RPM; van Houdt WJ; Eriksson H; Klop WMC; Ch'ng S; van Thienen JV; Mallo H; Gonzalez M; Acosta AT; Grijpink-Ongering LG; van der Wal A; Bruining A; van de Wiel BA; Scolyer RA; Haanen JBAG; Schumacher TN; van Akkooi ACJ; Long GV; Blank CU
Article: BRITISH JOURNAL OF DERMATOLOGY. 2023;188(1):32-40
Association of metformin use and survival in patients with cutaneous melanoma and diabetes
Krakowski I; Habel H; Nielsen K; Ingvar C; Andersson TML; Girnita A; Smedby KE; Eriksson H
Article: CANCERS. 2022;14(3):702
Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors
Costa Svedman F; Jalsenius M; Hoeiom V; Grozman V; Bergqvist M; Soederdahl F; Eriksson H; Rotstein S; Ny L; Ascierto PA; Brage SE; Helgadottir H
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2022;386(1):24-34
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Tawbi HA; Schadendorf D; Lipson EJ; Ascierto PA; Matamala L; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; De Menezes JJ; Dalle S; Arance A; Grob J-J; Srivastava S; Abaskharoun M; Hamilton M; Keidel S; Simonsen KL; Sobiesk AM; Li B; Hodi FS; Long GV; RELATIVITY-047 Investigators
Article: GENETICS IN MEDICINE. 2022;24(1):157-169
Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma
Yang M; Johnsson P; Brautigam L; Yang XR; Thrane K; Gao J; Tobin NP; Zhou Y; Yu R; Nagy N; Engstrom PG; Tuominen R; Eriksson H; Lundeberg J; Tucker MA; Goldstein AM; Egyhazi-Brage S; Zhao J; Cao Y; Hoiom V
Article: CANCERS. 2021;13(16):4164
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
Madonna G; Masucci GV; Capone M; Mallardo D; Grimaldi AM; Simeone E; Vanella V; Festino L; Palla M; Scarpato L; Tuffanelli M; D'angelo G; Villabona L; Krakowski I; Eriksson H; Simao F; Lewensohn R; Ascierto PA
Article: NEOPLASIA: AN INTERNATIONAL JOURNAL FOR ONCOLOGY RESEARCH. 2021;23(8):783-791
Plasma proteome alterations by MAPK inhibitors in BRAF^V600-mutated metastatic cutaneous melanoma
Babacic H; Eriksson H; Pernemalm M
Article: CANCERS. 2021;13(11):2838
Trend Shifts in Age-Specific Incidence for In Situ and Invasive Cutaneous Melanoma in Sweden
Eriksson H; Nielsen K; Vassilaki I; Lapins J; Mikiver R; Lyth J; Isaksson K
Article: ANNALS OF ONCOLOGY. 2021;32(6):766-777
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma
Rawson RV; Adhikari C; Bierman C; Lo SN; Shklovskaya E; Rozeman EA; Menzies AM; van Akkooi ACJ; Shannon KF; Gonzalez M; Guminski AD; Tetzlaff MT; Stretch JR; Eriksson H; van TJV; Wouters MW; Haanen JBAG; Klop WMC; Zuur CL; van Houdt WJ; Nieweg OE; Ch'ng S; Rizos H; Saw RPM; Spillane AJ; Wilmott JS; Blank CU; Long GV; van de Wiel BA; Scolyer RA
Article: CANCERS. 2021;13(10):2456
The Proportion Cured of Patients with Resected Stage II-III Cutaneous Melanoma in Sweden
Eriksson H; Utjes D; Olofsson Bagge R; Gillgren P; Isaksson K; Lapins J; Schultz IL; Lyth J; Andersson TM-L
Article: NATURE MEDICINE. 2021;27(2):256-263
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma
Rozeman EA; Hoefsmit EP; Reijers ILM; Saw RPM; Versluis JM; Krijgsman O; Dimitriadis P; Sikorska K; van de Wiel BA; Eriksson H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; Shannon K; Haanen JBAG; Stretch J; Ch'ng S; Nieweg OE; Mallo HA; Adriaansz S; Kerkhoven RM; Cornelissen S; Broeks A; Klop WMC; Zuur CL; van Houdt WJ; Peeper DS; Spillane AJ; van Akkooi ACJ; Scolyer RA; Schumacher TNM; Menzies AM; Long GV; Blank CU
Article: BRITISH JOURNAL OF DERMATOLOGY. 2021;184(1):60-67
Survival in 31 670 patients with thin melanomas: a Swedish population-based study
Isaksson K; Mikiver R; Eriksson H; Lapins J; Nielsen K; Ingvar C; Lyth J
Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(1):105-115
Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting
Krakowski I; Bottai M; Habel H; Masucci G; Girnita A; Smedby KE; Eriksson H
Article: CANCERS. 2020;12(11):E3228-3228
The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma-A Nation-Wide Swedish Population-Based Retrospective Register Study
Katsarelias D; Eriksson H; Mikiver R; Krakowski I; Nilsson JA; Ny L; Olofsson Bagge R
Article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(14):1591-1601
Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram
Maurichi A; Miceli R; Eriksson H; Newton-Bishop J; Nsengimana J; Chan M; Hayes AJ; Heelan K; Adams D; Patuzzo R; Barretta F; Gallino G; Harwood C; Bergamaschi D; Bennett D; Lasithiotakis K; Ghiorzo P; Dalmasso B; Manganoni A; Consoli F; Mattavelli I; Barbieri C; Leva A; Cortinovis U; Espeli V; Mangas C; Quaglino P; Ribero S; Broganelli P; Pellacani G; Longo C; Del Forno C; Borgognoni L; Sestini S; Pimpinelli N; Fortunato S; Chiarugi A; Nardini P; Morittu E; Florita A; Cossa M; Valeri B; Milione M; Pruneri G; Zoras O; Anichini A; Mortarini R; Santinami M
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2020;8(1):e000204
In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
Babacic H; Lehtio J; de Coana YP; Pernemalm M; Eriksson H
Article: FRONTIERS IN ONCOLOGY. 2020;10:51
Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma
Rad Pour S; Morikawa H; Kiani NA; Gomez-Cabrero D; Hayes A; Zheng X; Pernemalm M; Lehtio J; Mole DJ; Hansson J; Eriksson H; Tegner J
Article: THE LANCET. 2019;394(10197):471-477
2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial
Utjes D; Malmstedt J; Teras J; Drzewiecki K; Gullestad HP; Ingvar C; Eriksson H; Gillgren P
Article: THE LANCET ONCOLOGY. 2019;20(7):948-960
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Article: CANCER RESEARCH. 2018;78(20):5970-5979
Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma
Thrane K; Eriksson H; Maaskola J; Hansson J; Lundeberg J
Article: PLOS ONE. 2018;13(11):e0206942
Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma
Svedman FC; Lohcharoenkal W; Bottai M; Brage SE; Sonkoly E; Hansson J; Pivarcsi A; Eriksson H
Article: INTERNATIONAL JOURNAL OF CANCER. 2017;141(11):2243-2252
Reduced disease-specific survival following a diagnosis of multiple primary cutaneous malignant melanomas-a nationwide, population-based study
Utjes D; Lyth J; Lapins J; Eriksson H
Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2017;31(9):1468-1474
Prognostic risk factors of first recurrence in patients with primary stages I-II cutaneous malignant melanoma - from the population-based Swedish melanoma register
Lyth J; Falk M; Maroti M; Eriksson H; Ingvar C
Article: LAKARTIDNINGEN. 2017;114:ELAT
[Every second hour there is a new melanoma diagnosed in Sweden].
Ingvar C; Eriksson H
Article: PIGMENT CELL AND MELANOMA RESEARCH. 2017;30(1):76-156
13th International Congress of the Society for Melanoma Research, Boston, MA, USA, November 6-9, 2016 Abstracts
Article: INTERNATIONAL JOURNAL OF CANCER. 2016;139(3):543-553
Prognostic factors and disease-specific survival among immigrants diagnosed with cutaneous malignant melanoma in Sweden
Simberg-Danell C; Lyth J; Mansson-Brahme E; Frohm-Nilsson M; Carstensen J; Hansson J; Eriksson H
Article: GENES CHROMOSOMES AND CANCER. 2016;55(7):601-611
The Role of Germline Alterations in the DNA Damage Response Genes BRIP1 and BRCA2 in Melanoma Susceptibility
Tuominen R; Engstrom PG; Helgadottir H; Eriksson H; Unneberg P; Kjellqvist S; Yang M; Linden D; Edsgard D; Hansson J; Hoiom V
Article: INTERNATIONAL JOURNAL OF CANCER. 2016;138(12):2829-2836
The proportion cured of patients diagnosed with Stage III-IV cutaneous malignant melanoma in Sweden 1990-2007: A population-based study
Eriksson H; Lyth J; Andersson TM-L
Article: JAMA DERMATOLOGY. 2015;151(4):410-416
BRAF^V600E Protein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases
Eriksson H; Zebary A; Vassilaki I; Omholt K; Ghaderi M; Hansson J
Article: BRITISH JOURNAL OF DERMATOLOGY. 2015;172(3):700-706
Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men
Lyth J; Eriksson H; Hansson J; Ingvar C; Jansson M; Lapins J; Mansson-Brahme E; Naredi P; Stierner U; Ullenhag G; Carstensen J; Lindholm C
Article: BRITISH JOURNAL OF DERMATOLOGY. 2015;172(1):175-186
Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study
Eriksson H; Frohm-Nilsson M; Jaras J; Kanter-Lewensohn L; Kjellman P; Mansson-Brahme E; Vassilaki I; Hansson J
Article: JOURNAL OF AMERICAN ACADEMY OF DERMATOLOGY. 2014;71(2):245-248
Risk of cutaneous malignant melanoma in patients with celiac disease: A population-based study
Lebwohl B; Eriksson H; Hansson J; Green PHR; Ludvigsson JF
Article: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(13):1356-1364
Later Stage at Diagnosis and Worse Survival in Cutaneous Malignant Melanoma Among Men Living Alone: A Nationwide Population-Based Study From Sweden
Eriksson H; Lyth J; Mansson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Carstensen J; Hansson J
Article: CANCER EPIDEMIOLOGY. 2014;38(1):93-99
Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: A population-based study
Andersson TM-L; Eriksson H; Hansson J; Mansson-Brahme E; Dickman PW; Eloranta S; Lambe M; Lambert PC
Article: PIGMENT CELL AND MELANOMA RESEARCH. 2013;26(6):932-1019
10th International Congress of the Society for Melanoma Research, Philadelphia, PA, USA, November 17-20, 2013 Abstracts
Article: EUROPEAN JOURNAL OF CANCER. 2013;49(12):2705-2716
Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: A nationwide population-based study in Sweden
Eriksson H; Lyth J; Mansson-Brahme E; Frohm-Nilsson M; Ingvar C; Lindholm C; Naredi P; Stierner U; Wagenius G; Carstensen J; Hansson J
Article: ACTA DERMATO-VENEREOLOGICA. 2013;93(4):411-416
Interobserver Variability of Histopathological Prognostic Parameters in Cutaneous Malignant Melanoma: Impact on Patient Management
Eriksson H; Frohm-Nilsson M; Hedblad M-A; Hellborg H; Kanter-Lewensohn L; Krawiec K; Lundh Rozell B; Mansson-Brahme E; Hansson J
Article: GENES CHROMOSOMES AND CANCER. 2013;52(4):378-384
Hereditary uveal melanoma: A report of a germline mutation in BAP1
Hoiom V; Edsgard D; Helgadottir H; Eriksson H; All-Ericsson C; Tuominen R; Ivanova I; Lundeberg J; Emanuelsson O; Hansson J
Article: ARCHIVES OF DERMATOLOGY. 2008;144(5):612-616
A retrospective analysis of patients with bullous pemphigoid treated with methotrexate
Kjellman P; Eriksson H; Berg P
Visa fler

Alla övriga publikationer

Review: NPJ DIGITAL MEDICINE. 2024;7(1):78
Human-AI interaction in skin cancer diagnosis: a systematic review and meta-analysis
Krakowski I; Kim J; Cai ZR; Daneshjou R; Lapins J; Eriksson H; Lykou A; Linos E
Review: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. 2023;183:103919
Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review
Egeler MD; van Leeuwen M; Fraterman I; van den Heuvel NMJ; Boekhout AH; Lai-Kwon J; Wilthagen EA; Eriksson H; Haanen JB; Wilgenhof S; Ascierto PA; van Akkooi ACJ; van de Poll-Franse LV
Letter: ACTA ONCOLOGICA. 2022;61(7):869-873
Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial
Backlund E; Yang M; Grozman V; Masucci G; Falkenius J; Eriksson H; Jovanovic B; Hammarlund K; Isacsson U; Radu C; Abel E; Karlsson K; Palanco Zamora R; Wersall P; Edback U; Wickstrom S; Darai Ramqvist E; Egyhazi Brage S; Kiessling R; Viktorsson K; Franzen B; Lewensohn R; Olofsson Bagge R; Ullenhag GJ; Ny L; Lindberg K; Helgadottir H
Review: LAKARTIDNINGEN. 2021;118:21114
[Overview of immune-related side effects from immune checkpoint inhibitors. Part 2: Endocrine, rheumatologic and skin toxicity].
Helgadottir H; Falkenius J; Eriksson H; Girnita A; Sahlberg L; Bensing S; Chatzidionysiou K; Masucci G; Ullenhag G
Meeting abstract: ANNALS OF ONCOLOGY. 2021;32:S1223-S1224
Gender difference in side effects of immunotherapy: A possible clue to optimize cancer treatment
Miceli R; Eriksson H; Eustace AJ; Lo Russo G; Ballot J; Bergamini C; Bjaanaes MM; Corti F; De Cecco L; Frisardi L; Giannatempo P; Verzoni E; Helland A; Crown JP
Corrigendum: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2021;35(6):1407
Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting (vol 35, pg 105, 2021)
Krakowski I; Bottai M; Habel H; Masucci G; Girnita A; Smedby KE; Eriksson H
Editorial comment: CANCERS. 2020;13(1):E92-92
Reply to Comment on Katsarelias, D., et al. "The Effect of Beta-Adrenergic Blocking Agents in Cutaneous Melanoma-A Nation-Wide Swedish Population-Based Retrospective Register Study." Cancers 2020, 12, 3228
Katsarelias D; Eriksson H; Mikiver R; Krakowski I; Nilsson JA; Ny L; Olofsson Bagge R
Editorial comment: ACTA DERMATO-VENEREOLOGICA. 2020;100(18):adv00334-0
Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma
Eriksson H; Hansson J; Krynitz B; Masucci G; Girnita A; Lapins J; Huen AO; Tawbi HA; Davies MA; Tetzlaff MT; Curry JL
Meeting abstract: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2020;8:A2
UPDATE OF THE OPACIN AND OPACIN-NEO TRIALS: 36-MONTHS AND 24-MONTHS RELAPSE-FREE SURVIVAL AFTER (NEO)ADJUVANT IPILIMUMAB PLUS NIVOLUMAB IN MACROSCOPIC STAGE III MELANOMA PATIENTS
Versluis JM; Rozeman EA; Menzies AM; Reijers ILM; Krijgsman O; Hoefsmit EP; de Wiel BAV; Sikorska K; Bierman C; Dimitriadis P; Gonzalez M; Broeks A; Kerkhoven RM; Spillane AJ; Haanen JBAG; van Houdt WJ; Saw RPM; Eriksson H; van Akkooi ACJ; Scolyer RA; Schumacher TN; Long GV; Blank CU
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(27):3238-3240
Sentinel Node Biopsy in Patients With Thin Melanoma: A Need to Better Define the Aim Reply
Maurichi A; Miceli R; Eriksson H; Newton-Bishop J; Nsengimana J; Chan M; Hayes AJ; Heelan K; Adams D; Patuzzo R; Barretta F; Gallino G; Harwood C; Bergamaschi D; Bennett D; Lasithiotakis K; Ghiorzo P; Dalmasso B; Manganoni A; Consoli F; Mattavelli I; Barbieri C; Leva A; Cortinovis U; Espeli V; Mangas C; Quaglino P; Ribero S; Broganelli P; Pellacani G; Longo C; Del Forno C; Borgognoni L; Sestini S; Pimpinelli N; Fortunato S; Chiarugi A; Nardini P; Morittu E; Florita A; Cossa M; Valeri B; Milione M; Pruneri G; Zoras O; Anichini A; Mortarini R; Santinami M
Meeting abstract: ANNALS OF ONCOLOGY. 2020;31:S760
Plasma proteomics in patients with metastatic cutaneous melanoma treated with targeted therapy
Eriksson H; Babacic H; Lehtio J; Pernemalm M
Meeting abstract: CANCER RESEARCH. 2020;80(16):3412
36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials
Blank CU; Versluis JM; Rozeman EA; Menzies AM; Reijers IL; Krijgsman O; Hoefsmit EP; van de Wiel BA; Sikorska K; Bierman C; Dimitriadis P; Gonzalez M; Broeks A; Kerkhoven RM; Spillane AJ; Haanen JB; van Houdt WJ; Saw RP; Eriksson H; van Akkooi AC; Scolyer RA; Schumacher TN; Long GV
Meeting abstract: CANCER RESEARCH. 2020;80(16):3271
Different pathologic response rates between Australia and Europe in macroscopic stage III melanoma patients upon neoadjuvant ipilimumab plus nivolumab in the phase II OpACIN-neo trial
Reijers IL; Rozeman EA; Menzies AM; Versluis JM; van de Wiel BA; Sikorska K; Eriksson H; Shannon K; Bierman C; van Tinteren H; Gonzalez M; Spillane AJ; Saw RP; van Akkooi AC; Scolyer RA; Hansson J; Long GV; Blank CU
Letter: ALLERGY. EUROPEAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2020;75(8):2096-2099
Desloratadine and loratadine use associated with improved melanoma survival
Fritz I; Wagner P; Bottai M; Eriksson H; Ingvar C; Krakowski I; Nielsen K; Olsson H
Editorial comment: ACTA ONCOLOGICA. 2020;59(3):247-248
Immune checkpoint inhibitors in cancer treatment and potential effect modification by age
Eriksson H; Smedby KE
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):tps9605
Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.
Reijers I; Rozeman EA; Menzies AM; Van de Wiel BA; Eriksson H; Suijkerbuijk K; Van der Veldt AAM; Kapiteijn E; Hospers G; Klop WMC; Spillane A; Scolyer RA; Svane IM; Bastholt L; Schmidt H; Larkin JMG; Van Akkooi ACJ; Long GV; Blank CU
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(15):9574
Plasma proteomic analyses and treatment predictive biomarker candidates in melanoma patients receiving immune checkpoint blockade or targeted therapy.
Eriksson H; Babacic H; Lehtio J; Pernemalm M
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):e21587
Dissecting genetic heterogeneity in stage III cutaneous malignant melanoma with spatially resolved transcriptomics.
Eriksson H; Thrane K; Maaskola J; Hansson J; Lundeberg J
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2017;35:tps9600
Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).
Rozeman EA; Christopher A; Van Akkooi J; Routier E; Menzies AM; Eriksson H; Smith M; Scolyer RA; Hoeller C; Hansson J; Robert C; Larkin JMG; Long GV; Blank CU
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):9579
Exosomal microRNAs as putative predictive biomarkers for targeted therapy in stage IV cutaneous malignant melanoma (CMM).
Eriksson H; Lohcharoenkal W; Costa-Svedman F; Sonkoly E; Brage SE; Hansson J; Pivarcsi A
Thesis / dissertation: 2013
Clinical and epidemiological studies on prognostic and predicitve factors in cutaneous melanoma
Eriksson, Hanna
Visa fler

Anställningar

Anknuten till Forskning, Onkologi-Patologi, Karolinska Institutet, 2023-2026

Examina och utbildning

Docent, onkologi, Karolinska Institutet, 2021
Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2013
Läkarexamen, Karolinska Institutet, 2002

Handledare

Anna Oksanen, Loss of life expectancy for patients with malignant melanoma, by socioeconomic groups and sex, 2023

Om mig

Forskningsbeskrivning

Undervisning

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Handledare

Nyheter från KI

Kalenderhändelser från KI